# Render Biotech Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/render-biotech-co

- Industry: Medical Devices & Equipment
- Headquarters: Shenzhen, China
- Website: www.renderbio.com
- Total disclosed funding: $15M
- Latest round: Series A (Jul 6, 2021)
- Investors on record: 3

## About

Render Biotech Co., Ltd. is a healthcare technology company specializing in innovative solutions for hemostasis, point-of-care testing, and microbiology, aimed at improving diagnostic accuracy and patient care.Founded in 2010 in Shenzhen, China, Render Biotech Co., Ltd. focuses on high-tech healthcare solutions. The company has engaged in 2 notable deals, with the most recent deal occurring on July 6, 2021. Render Biotech raised USD 15.00 mn in Series A funding led by Qiming Venture Partners, with participation from Sequoia Capital. The firm's founder has a background in the healthcare technology sector, with this venture representing a culmination of prior expertise and innovation in the field.Render Biotech Co., Ltd. specializes in high-tech healthcare solutions, primarily focusing on hemostasis, point-of-care testing (POCT), and microbiology products. Their offerings are designed to enhance diagnostic accuracy and efficiency in clinical environments, addressing critical needs in patient care and disease management. These products are utilized in various healthcare settings, including hospitals, clinics, and laboratories, allowing healthcare professionals to obtain rapid and reliable test results. Render Biotech's solutions cater to a diverse client base that includes healthcare providers and laboratories across international markets, with notable distribution in Asia, Europe, and North America. The company is committed to innovation and quality, ensuring that their products meet the evolving demands of the healthcare industry.Render Biotech Co., Ltd. generates revenue through a structured model involving direct sales to healthcare facilities and partnerships with distributors. The company's business transactions typically encompass bulk orders and contractual agreements with healthcare providers, allowing for streamlined procurement processes. Render Biotech’s flagship products, such as their hemostasis and microbiology testing kits, are positioned at competitive pricing, appealing to both B2B clients and direct consumers. This transactional framework supports sustained revenue growth by fostering long-term relationships with healthcare institutions and ensuring a steady demand for their innovative products. The company’s commitment to high-quality healthcare solutions positions it favorably within the global market landscape.Render Biotech Co., Ltd. plans to utilize the recent USD 15.00 mn Series A funding to enhance its product pipelines and strengthen its sales and marketing teams as well as its supply chain. The company is focused on designing and launching new products in the hemostasis and POCT sectors, with anticipated releases throughout 2022. Additionally, Render Biotech aims to expand its reach into new markets, specifically targeting growth in Europe and North America by the end of 2023.

## Funding rounds

- Series A, Jul 6, 2021, $15M — Hong Shan, Qiming Venture Partners
- Angel, Jun 1, 2019 — ASB Ventures

## Investors

- ASB Ventures (https://capitalatlas.ai/funds/asb-ventures) — Angel
- Hong Shan — Series A
- Qiming Venture Partners (https://capitalatlas.ai/funds/qiming-venture-partners) — Series A